Travere Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2008
NCT00007020
First Marketed Drug
2015
cholic acid (cholbam)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Retrophin, Inc. | TRAVERE

Active Ingredients

Marketed Drugs (1)

cholic acid (cholbam) (2015)

Drugs in Phase 3 Trials (5)

Key: Travere (4) Acquired (1)

cholic acid (cholbam) (3 trials)

fosmetpantotenate (1 trial)

irbesartan (avapro) (3 trials)

pegylated arginine deiminase (4 trials)

sparsentan (3 trials)

Drugs in Phase 2 Trials (3)

Key: Travere (0) Acquired (3)

acn00177 (1 trial)

agle 103 (1 trial)

pembrolizumab (keytruda) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Travere (0) Acquired (2)

agle-102 (1 trial)

co-argi-peg (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenoleukodystrophy (Phase 3)

Cholestasis (Phase 3)

Glomerulonephritis, IGA (Phase 3)

Glomerulosclerosis, Focal Segmental (Phase 3)

Kidney Diseases (Phase 3)

Nerve Degeneration (Phase 3)

Pantothenate Kinase-Associated Neurodegeneration (Phase 3)

Peroxisomal Disorders (Phase 3)

Refsum Disease (Phase 3)

Refsum Disease, Infantile (Phase 3)

Zellweger Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 10